Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb 13:15:1333534.
doi: 10.3389/fpsyt.2024.1333534. eCollection 2024.

Discovery of a novel cytokine signature for the diagnosis of autism spectrum disorder in young Arab children in Qatar

Affiliations

Discovery of a novel cytokine signature for the diagnosis of autism spectrum disorder in young Arab children in Qatar

Wared Nour-Eldine et al. Front Psychiatry. .

Abstract

Background: Autism spectrum disorder (ASD) is a heterogeneous neurodevelopmental disorder characterized by impaired social interaction and communication and the occurrence of stereotyped and repetitive behaviors. Several studies have reported altered cytokine profiles in ASD and hence may serve as potential diagnostic biomarkers of the disorder. This study aims to identify diagnostic biomarkers for ASD in a well-defined study cohort in Qatar.

Methods: We measured the protein levels of 45 cytokines in the plasma samples of age- and gender-matched children (2-4 years) with ASD (n = 100) and controls (n = 60) using a Luminex multiplex assay. We compared the differences in the levels of these cytokines between the two study groups and then fitted the significantly altered cytokines into a logistic regression model to examine their diagnostic potential for ASD.

Results: We found elevated levels of IFN-γ, FGF-2, IL-1RA, and IL-13 and reduced levels of eotaxin, HGF, IL-1 alpha, IL-22, IL-9, MCP-1, SCF, SDF-1 alpha, VEGFA, and IP-10 in the plasma of children with ASD compared to controls. Furthermore, we observed that elevated levels of IFN-γ (odds ratio (OR) = 1.823; 95% (confidence interval) CI = 1.206, 2.755; p = 0.004) and FGF-2 (OR = 2.528; 95% CI = 1.457, 4.385; p < 0.001) were significantly associated with increased odds of ASD, whereas reduced levels of eotaxin (OR = 0.350; 95% CI = 0.160, 0.765; p = 0.008) and HGF (OR = 0.220; 95% CI = 0.070, 0.696; p = 0.010) were significantly associated with lower odds of ASD relative to controls. The combination of these four cytokines revealed an area under the curve (ROC-AUC) of 0.829 (95% CI = 0.767, 0.891; p < 0.001), which demonstrates the diagnostic accuracy of the four-cytokine signature.

Conclusions: Our results identified a panel of cytokines that could discriminate between children with ASD and controls in Qatar. In addition, our findings support the predominance of a Th1 immune phenotype in ASD children and emphasize the need to validate these results in larger populations.

Keywords: ASD; autism spectrum disorder; biomarkers; cytokines; logistic regression; luminex multiplex assay.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Receiver operating characteristic (ROC) curves demonstrate the ability of the selected cytokines to differentiate between ASD and control cases. (A) ROC curve is illustrated for the combination of the four predictors. (B) The area under the ROC curve (AUC), 95% confidence interval (CI) and p-value are displayed in table for the individual and combined predictors. AUC values above 0.5 suggest a positive association with ASD, whereas AUC values below 0.5 suggest a negative association. The black line is the reference line.

Similar articles

Cited by

References

    1. Zeidan J, Fombonne E, Scorah J, Ibrahim A, Durkin MS, Saxena S, et al. . Global prevalence of autism: A systematic review update. Autism Res (2022) 15(5):778–90. doi: 10.1002/aur.2696 - DOI - PMC - PubMed
    1. Lord C, Elsabbagh M, Baird G, Veenstra-Vanderweele J. Autism spectrum disorder. Lancet (2018) 392(10146):508–20. doi: 10.1016/S0140-6736(18)31129-2 - DOI - PMC - PubMed
    1. Lord C, Charman T, Havdahl A, Carbone P, Anagnostou E, Boyd B, et al. . The Lancet Commission on the future of care and clinical research in autism. Lancet (2022) 399(10321):271–334. doi: 10.1016/S0140-6736(21)01541-5 - DOI - PubMed
    1. Gladysz D, Krzywdzinska A, Hozyasz KK. Immune abnormalities in autism spectrum disorder-could they hold promise for causative treatment? Mol Neurobiol (2018) 55(8):6387–435. doi: 10.1007/s12035-017-0822-x - DOI - PMC - PubMed
    1. Onore C, Careaga M, Ashwood P. The role of immune dysfunction in the pathophysiology of autism. Brain Behav Immun (2012) 26(3):383–92. doi: 10.1016/j.bbi.2011.08.007 - DOI - PMC - PubMed